PAS
ESPR

Point72 Asia (Singapore)’s Esperion Therapeutics ESPR Stock Holding History

Point72 Asia (Singapore)’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-114,371
Closed -$307K – 1162
2024
Q1 		$307K Buy
114,371
+94,171
+466% +$229K 0.08% 275
2023
Q4 		$60.4K Buy
+20,200
New +$26.2K 0.01% 284

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Point72 Asia (Singapore)'s ESPR Position: Q2 2024 in Review

Point72 Asia (Singapore) sold out of Esperion Therapeutics (ESPR) in Q2 2024, closing a stake of 114,371 shares — an estimated $307K sold.

Point72 Asia (Singapore) first reported a position in ESPR in Q4 2023 and held it in 2 quarters. The position peaked at $307K in Q1 2024. 176 funds tracked by Wall St. Rank hold ESPR as of Q2 2024.

  • Point72 Asia (Singapore) reported no remaining Esperion Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 114,371 Esperion Therapeutics shares in Q2 2024, an estimated $307K.
  • Point72 Asia (Singapore) first reported a position in Esperion Therapeutics in Q4 2023 and held it in 2 quarters.
  • Point72 Asia (Singapore)'s Esperion Therapeutics position peaked at $307K in Q1 2024.
  • 176 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2024.

Based on Point72 Asia (Singapore)'s 13F filing for Q2 2024, filed 14 Aug 2024.